Methotrexate
- Generic Name
- Methotrexate
- Brand Names
- Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo
- Drug Type
- Small Molecule
- Chemical Formula
- C20H22N8O5
- CAS Number
- 59-05-2
- Unique Ingredient Identifier
- YL5FZ2Y5U1
- Background
Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.
Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments.
Methotrexate was granted FDA approval on 7 December 1953.
- Indication
Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
Other formulations are indicated to treat gestational choriocarcinoma, chorioadenoma destruens, hydatiform mole, breast cancer, epidermoid cancer of the head and neck, advanced mycosis fungoides, lung cancer, and advanced non-Hodgkin's lymphoma. It is also used in the maintenance of acute lymphocytic leukemia. Methotrexate is also given before treatment with leucovorin to prolong relapse-free survival following surgical removal of a tumour in non-metastatic osteosarcoma.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis
- Associated Therapies
- Medically induced abortion
Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 910
- Registration Number
- NCT01548001
- Locations
- 🇨🇳
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
- Conditions
- ChoriocarcinomaFIGO Stage I Gestational Trophoblastic TumorFIGO Stage II Gestational Trophoblastic TumorFIGO Stage III Gestational Trophoblastic TumorHydatidiform Mole
- Interventions
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2022-08-12
- Lead Sponsor
- GOG Foundation
- Target Recruit Count
- 57
- Registration Number
- NCT01535053
- Locations
- 🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChildhood Acute Myeloid Leukemia in RemissionChildhood Chronic Myelogenous LeukemiaChildhood Grade III Lymphomatoid GranulomatosisAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Interventions
- Drug: fludarabine phosphateDrug: melphalanRadiation: total-body irradiationDrug: tacrolimusDrug: mycophenolate mofetilDrug: methotrexateOther: laboratory biomarker analysisProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2012-02-09
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 94
- Registration Number
- NCT01529827
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Target Recruit Count
- 101
- Registration Number
- NCT01528163
- Locations
- 🇧🇪
Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium
🇱🇺Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg
🇧🇪Hôpital de Jolimont, Haine-Saint-Paul, Hainaut, Belgium
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Stage I Mantle Cell LymphomaStage II Contiguous Mantle Cell LymphomaStage II Non-Contiguous Mantle Cell LymphomaStage III Mantle Cell LymphomaStage IV Mantle Cell Lymphoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CyclophosphamideDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MethotrexateBiological: OfatumumabDrug: Vincristine Sulfate
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT01527149
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
- Conditions
- LeukemiaLymphomaMyelomaMyeloproliferative Diseases
- Interventions
- Drug: FludarabineDrug: MelphalanDrug: AlemtuzumabProcedure: Stem Cell InfusionDrug: TacrolimusDrug: MethotrexateDrug: G-CSFProcedure: Low Dose Donor T-CellsProcedure: High Dose Donor T-Cells
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT01518153
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation
- Conditions
- Acute Lymphocytic LeukemiaAcute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2011-12-14
- Last Posted Date
- 2018-01-23
- Target Recruit Count
- 40
- Registration Number
- NCT01491958
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
- Conditions
- LeukemiaLymphoma
- Interventions
- Drug: RituximabDrug: 111In IbritumomabProcedure: Planar Scintigraphy ImagingDrug: 90Y IbritumomabTiuxetanDrug: FludarabineDrug: BendamustineDrug: ThymoglobulinDrug: TacrolimusDrug: MethotrexateDrug: MycophenolateDrug: G-CSFProcedure: Stem Cell Transplantation
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2020-05-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01490723
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
- Conditions
- Acute Lymphoblastic LeukemiaPrecursor B-Cell Lymphoblastic LeukemiaPrecursor T-Cell Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2011-12-01
- Last Posted Date
- 2020-10-27
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 23
- Registration Number
- NCT01483690
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
🇦🇺Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇦🇺Sydney Children's Hospital, Sydney, Australia
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- Drug: OfatumumabDrug: EtoposideDrug: IfosfamidDrug: MesnaDrug: CytarabineDrug: MethotrexateDrug: LeukovorinDrug: Granulocyte-Colony Stimulating Factor
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Polish Lymphoma Research Group
- Target Recruit Count
- 77
- Registration Number
- NCT01481272
- Locations
- 🇵🇱
Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland
🇵🇱Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland
🇵🇱Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.